REQUEST A DEMO
Total
USD $0.00
Search more companies

Sindan - Pharma SRL (Romania)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Sindan - Pharma SRL Profile Updated: August 22, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

In March 2006, Actavis acquired Sindan following a transaction of EUR 147.5 mil. This acquisition offered Actavis access to a new pharmaceutical domain, as well as the possibility of a sound development and experience in the production of oncologic medicine.
In 2008, SC SINDAN SRL, one of the Sindan - Pharma SRL's associates changed its name to SC ACTAVIS SRL.

Headquarters
Bulevardul Ion Mihalache Nr. 11
Bucharest; Bucharest;

Contact Details: Purchase the Sindan - Pharma SRL report to view the information.

Basic Information
Total Employees:
Purchase the Sindan - Pharma SRL report to view the information.
Outstanding Shares:
Purchase the Sindan - Pharma SRL report to view the information.
Registered Capital:
Purchase the Sindan - Pharma SRL report to view the information.
Financial Auditors:
Purchase the Sindan - Pharma SRL report to view the information.
Incorporation Date:
February 06, 2003
Key Executives
Purchase this report to view the information.
Administrator
Purchase this report to view the information.
Administrator
Purchase this report to view the information.
Administrator
Ownership Details
Purchase this report to view the information.
99.4%
Purchase this report to view the information.
0.6%
Company Performance
Financial values in the chart are available after Sindan - Pharma SRL report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RON. Absolute financial data is included in the purchased report.
Net sales revenue
8.94%
Total operating revenue
9%
Operating profit (EBIT)
-13.15%
EBITDA
-5.9%
Net Profit (Loss) for the Period
-9.05%
Total assets
-36.95%
Total equity
-44.23%
Operating Profit Margin (ROS)
-1.79%
Net Profit Margin
-1.62%
Return on Equity (ROE)
3.97%
Quick Ratio
-2.45%
Cash Ratio
-0%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?